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Abstract 
Background: Little information is available on the long-term outcomes of patients with 
localised prostate cancer.  
Objective: To examine the long-term survival of patients with localised prostate gland car-
cinoma T1 – T2, N0, M0 (UICC stage I and II) compared to the normal population. 
Design: Retrospective cohort. 
Setting: Regensburg, Germany. 
Participants: Data on 2121 patients with histologically-confirmed, localised prostate cancer 
diagnosed between 1998 and 2007 were extracted from the cancer registry of the tumour 
centre in Regensburg, Germany.  
Measurements: Overall survival rate in the patient cohort was estimated and compared to 
the expected survival rate of a comparable group in the general population derived from the 
official life-tables of Germany stratified by age, sex and calendar year. 
Results: Ten years after diagnosis, patients with stage I and II localised prostate gland car-
cinoma had an approximately 10% increase in survival compared to the normal male popu-
lation (Relative Survival = 110.7%, 95%-CI 106.6 - 114.8%). 
Limitations: We did not examine the effect of cancer treatment or cancer aggressiveness on 
the overall survival of patients. We did not assess the incidence of subsequent non-primary 
cancers in our patient population or how this incidence affects the patients’ follow-up care and 
survival. 
Conclusions:  Patients with stage I+II localised prostate gland carcinoma have improved 
survival compared with the normal male population. This finding cannot be explained solely by 
the administration of prostate carcinoma treatments, suggesting that men who participate in 
PSA screening may have better overall health behaviors and care than men who do not par-
ticipate in screening. Future research should examine how treatment choice, especially an 
“active surveillance” approach to care, affects survival in these patients more than ten years 
after diagnosis. 
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Introduction 
The incidence of prostate cancer has increased in 
industrialized  nations  worldwide  in  the  past  three 
decades (1). Today, almost 20% of men over 50 years 
old will receive a prostate cancer diagnosis, and be-Journal of Cancer 2011, 2 
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tween 1979 and 2006 the detection of prostate cancer 
increased  among  men  less  than  65  years  of  age  by 
approximately  4.1-fold  (1).  These  increases  can  be 
explained in-part by the implementation of extensive 
prostate-specific  antigen  (PSA)  screening  programs 
and the aging populations of industrialized nations 
(2,3).  
Although PSA testing increases prostate cancer 
incidence by improving the ability to detect prostate 
cancer  cases  in  a  population,  it  also  allows  for  the 
recognition  and  treatment  of  prostate  cancer  in  an 
early stage, thereby reducing the rate of death from 
prostate cancer (2,4). Due to this shift in the stage at 
which  men  receive  a  prostate  cancer  diagnosis, 
wide-scale use of traditional curative treatments for 
prostate cancer (such as radical prostatectomy), which 
come  with  medical  and  quality  of  life  side-effects, 
may not be justified. Indeed, the new guidelines of the 
Germany Society for Urology (DGU) (5) include "ac-
tive surveillance" as an acceptable therapy option for 
low-risk prostate cancer, but research is needed on the 
long-term survival of these patients and the effect of 
treatment  choice  on  survival  before  standardized 
treatment  recommendations  for  localised,  low-risk 
prostate cancer are possible. 
There have been limited data available on men 
with  localised  prostate  gland  carcinoma  in  Europe 
with  which  to  conduct  necessary  research  on  the 
long-term survival of patents with low-risk prostate 
cancer (6). The creation of regional cancer registries in 
the  past  10-15  years,  including  that  of  the  Federal 
Republic  of  Germany  (FRG),  has  provided  for  the 
opportunity  to  close  this  research  gap.  In  order  to 
investigate the long-term outcomes of patients with 
localised  prostate  carcinoma  in  Germany,  we  used 
data from the regional tumour registry in Regensburg, 
Germany to evaluate the relative survival of patients 
with localised prostate gland carcinoma, as compared 
to the standardised age-adjusted survival of the nor-
mal Bavarian population. 
Methods 
We extracted epidemiological and clinical data 
from  the  Regensburg  regional  tumour  registry  on 
patients  diagnosed  between  1998  and  2007  with 
prostate  cancer.  The  cancer  tumour  registry  of  Re-
gensburg is a population-based registry that records 
the diagnosis, treatment, and follow-up care of any 
known  malignancy  in  cancer  patients  living  in  the 
districts  of  Oberpfalz  and  Niederbayern,  Bavaria, 
Germany. The data for the registry are provided by 
primary  care  physicians,  hospital  staff  and 
pathologists  from  the  districts  using  standardised 
cancer registry forms. The registry captures more than 
90% of all persons diagnosed with cancer located in 
the two districts, which have a combined population 
of approximately 2 million residents (6). 
All patients included in this study had a histo-
logically-confirmed  prostate  carcinoma  (diagnosis 
C61),  based  on  the  International  Classification  of 
Diseases ICD-10 (8). The registry record for each pa-
tient included the initial clinical and the pathological 
stage  according  to  the  classification  of  the  Interna-
tional Union Against Cancer (UICC) (9). We used this 
classification to select patients with early and local-
ly-limited cancer UICC stages I and/or II, comprising 
patients with small tumour size (T1 and T2), negative 
nodal  status  (N0)  and  no  distant  metastasis  (M0). 
Although not part of our primary study objective, we 
also  selected  patients  with  stage  III  and  stage  IV 
prostate  cancer  to  evaluate  the  relative,  long-term 
survival in patients with later stage prostate carcino-
ma. We ascertained the life-status of the registry pa-
tients  using  death-certificates  and  information  from 
the registration offices of the patients’ respective res-
ident districts.  
We calculated overall survival rates and relative 
survival rates of the cancer patients at 5 and 10 years 
post-diagnosis. The cumulative relative survival rate 
is defined as the ratio of the observed overall survival 
rate in the patient group and the expected survival 
rate of a comparable group from the general popula-
tion matched with respect to age at diagnosis, sex and 
calendar year of diagnosis.  For this comparison the 
official  German  life-tables  from  1998  to  2007  were 
used,  stratified  according  to  age,  sex  and  calendar 
year. We applied the software SURVSOFT for calcu-
lating overall survival choosing the standard life table 
(actuarial) method with one-year time intervals and 
for calculating relative survival choosing the method 
of Hakulinen in order to estimate expected survival 
(10). All patients - regardless of length of follow-up - 
were included. We did not differentiate or control for 
the  types  of  cancer  treatments  received  by  the  pa-
tients, because we were interested in overall survival 
independent  of  treatment  choice.  Descriptive  data 
analyses were performed using the statistical software 
SPSS V.18.  
Results 
Table  1  shows  the  numbers,  average  ages  and 
length  of  follow-up  of  the  patients  included  in  our 
analyses.  Approximately  51%  of  all  diagnosed  tu-
mours in the registry data were stage I+II localised 
tumours. The average age at diagnosis was 67.2 years 
(median: 67.6), the average length of follow-up was 
6.4 years (median: 6.1). Table 2 and Figure 1 show the 
results of our overall survival calculations and relative Journal of Cancer 2011, 2 
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survival  analyses.  Patients  with  stage  I+II  prostate 
cancer  had  an  approximately  5%  increase  in  5-year 
survival compared to the normal population (Relative 
survival = 104.7%, 95%-CI 103.2 - 106.2%) and an ap-
proximately  10%  increase  in  10-year  survival  com-
pared with the normal population (Relative Survival 
= 110.7%, 95%-CI 106.6 - 114.8%; Table 2, Figure 1).  
Patients  with  stage  III  prostate  cancer  did  not 
have significantly different 5-year or 10-year survival 
rates than the normal population (Relative Survival = 
101.9%, 95%-CI 99.7 - 104.2% and 102.0%, 95%-CI 96.4 
- 107.5%, respectively; Table 2, Figure 1), while  pa-
tients  with  stage  IV  prostate  cancer  had  significant 
and clear 5-year and 10-year survival disadvantages 
compared to the normal population (Relative Survival 
= 54.4%, 95%-CI 50.7 - 58.0% and 43.4%, 95%-CI 38.1 - 
48.7%, respectively; Table 2, Figure 1).  
 
Table 1. Number, average age and follow-up of patients. 
  Sample  Age  Follow-up 
(years) 
Prostate Cancer 
Stage (UICC) 
N   %   Mean  Median  Mean   Median  
I+II  2121  50.6%  67.2  67.6  6.4  6.1 
III  954  22.8%  65.5  65.7  6.5  6.5 
IV  1113  26.6%  68.8  68.7  4.2  3.4 
Total  4188  100.0%  67.2  67.3  5.8  5.7 
UICC = International Union Against Cancer 
Table 2. Overall survival of patients, expected survival of comparable normal population, and relative survival of the patient 
cohorts at 5- and 10-years post-diagnosis by cancer stage. 
Prostate Cancer Stage 
(UICC) 
Overall Survival of Patient Cohort (%)  Expected Survival of Comparable 
Normal Population (%) 
Relative Survival of Patient Cohort (%) 
(95%-Confidence interval) 
   5Y  10Y  5Y  10Y  5Y  10Y 
I+II  90.2  76.5  86.2  69.1  104.7 
(103.2-106.2) 
110.7 
(106.6-114.8) 
III  89.9  75.0  88.2  73.6  101.9 
(99.7-104.2) 
102.0 
(96.4-107.5) 
IV  44.9  28.2  82.6  64.9  54.4 
(50.7-58.0) 
43.4 
(38.1-48.7) 
Total  78.2  63.0  85.7  69.0  91.2 
(89.7-92.7) 
91.4 
(88.4-94.4) 
UICC = International Union Against Cancer; Y = Number of years post-diagnosis 
 
 
 
 
Figure 1. Relative survival rates for the prostate cancer stage I+II, III and IV patient cohort. 
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Discussion 
Our  analyses  showed  that  patients  with  stage 
I+II  localised  prostate  gland  carcinoma  have  im-
proved survival compared to the normal male popu-
lation,  and  this  relative  survival  advantage  appears 
only 2-3 years after diagnosis (Figure 1). This finding 
cannot be explained definitively by the administration 
of prostate gland carcinoma treatments (e.g., radical 
prostatectomy,  radiotherapy),  which  have  been 
shown  to  result  in  a  survival  advantage  only  after 
several years (11,12,13).  
We suggest three primary explanations for our 
findings. First, as described in previous research, rel-
atively healthy men take advantage of PSA-supported 
preventive  measures  and  show  reduced  morbidity 
and improved survival compared to men who do not 
participate in PSA testing (14). Additionally, we know 
from the 2008 work of Fröhner et al. that in men 63 to 
69 years of age increased comorbidity is a strong pre-
dictor of 10-year mortality in men receiving radical 
prostatectomy (15). Our results support these findings 
by suggesting that the health of men who undergo 
PSA-testing, especially those in the 50-70 year-old age 
range, is better overall (i.e., lower comorbidity) than 
that of men who do not participate in PSA screening. 
Second, research has shown that a cancer diagnosis 
can be a ―teachable moment‖ that encourages patients 
to adopt better health behaviors (16,17). The men in 
our  sample  who  were  diagnosed  with  stage  I  or  II 
prostate cancer may have made more positive health 
choices  compared  to  the  general  population  in  the 
first  few  years  after  their  diagnosis.  Third,  the  ob-
served improved survival may result not only from 
the  superior  health-consciousness  and  behaviors  of 
cancer  patients,  but  also  from  socioeconomic  ad-
vantages (e.g., higher levels of education and income) 
that make one more like to receive secondary preven-
tion outreach by health care providers and the media 
(18,19,20). The socioeconomic disparities in secondary 
prevention outreach and up-take are cited as a major 
weakness of PSA screening systems. Furthermore it is 
well possible that physicians exercise a more careful 
patient selection for prostate cancer screening. 
The goal of treatment for prostate gland carci-
noma should be the effective delivery of care to every 
diagnosed  patient,  and  this  care  must  take  into  ac-
count  each  patient’s  individual  needs,  living  condi-
tions, and tumour biology. Our finding that men with 
stage  I+II  prostate  cancer  have  survival  advantages 
independent  of  treatment  choice  suggests  that  the 
current standards of care in Germany—which result 
in almost 70% of prostate cancer patients under the 
age  of  70  receiving  radical  prostatectomy—should 
change to include less invasive methods of treatment 
for  cancers  at  low  risk  of progression  (21).  Accord-
ingly,  several  European  treatment  guidelines  now 
include  ―active  surveillance‖  as  an  evidence-based 
method of treatment for localised, low-risk prostate 
carcinoma (5). 
Limitations to our study include the fact that we 
did  not  examine  the  effect  of  individual,  evi-
dence-based  treatments  for  localised  prostate  gland 
carcinoma  or  cancer  aggressiveness  (e.g.,  Gleason 
score) (21) on the overall survival of patients. We also 
did not evaluate whether all patients with stage I+II 
prostate cancer included in the study had underwent 
PSA screening to confirm our conclusion that the pa-
tients’ survival advantage related to their participa-
tion in PSA testing. Lastly, we did not assess the in-
cidence  of  subsequent  non-primary  cancers  in  our 
patient population or how this incidence affects the 
patients’ follow-up care and survival (21). We plan to 
conduct future analyses to examine these questions in 
the German population. 
Conclusion 
Patients with localised, stage I+II prostate gland 
carcinoma demonstrated improved long-term health 
compared to the normal population, regardless of the 
treatment received during the first ten years after di-
agnosis. The finding suggests that that men who par-
ticipate  in  PSA  screening  may  have  better  overall 
health behaviors and care than men who do not par-
ticipate in screening and that men who receive a can-
cer  diagnosis  may  make  positive  health  behavior 
changes  after  their  diagnosis  that  improve  their 
long-term survival. Future research should examine 
how treatment choice, especially an ―active surveil-
lance‖ approach to care, affects survival in these pa-
tients more than ten years after diagnosis. Research 
should also evaluate the long-term survival impact of 
socioeconomic  disparities  in  the  receipt  of  prostate 
cancer secondary prevention outreach and services. 
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